A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-17 and is reviewed periodically as new material appears.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
=== Sugar ring modifications === Another modification that is useful for medical applications of oligonucleotides is 2' sugar modifications. Modifying the 2' position sugar increases the effectiveness of oligonucleotides by enhancing the target binding capabilities of oligonucleotides, specifically in antisense oligonucleotides therapies. They also decrease non specific protein binding, increasing the accuracy of targeting specific proteins. Two of the most commonly used modifications are 2'-O-methyl and the 2'-O-methoxyethyl. Fluorescent modifications on the nucleobase was also reported.
In August, while appearing on an episode Alex Cooper's podcast Call Her Daddy, Hunter Schafer said, "The real tea is I have no fucking idea what's going on" with production on the series' third season. Zendaya said she did not "really have much of an answer" for the future of Euphoria other than it was set to start filming in January 2025. Colman Domingo said that Levinson had "told me some of it, and it's going to be groundbreaking." Angus Cloud's death from a drug overdose on July 31, 2023, impacted Levinson's teleplays. Speaking to The New York Times, he said "I had a good portion of it done before the strike [began in May 2023]. Angus was the backbone of that season. I used to even talk to him about it because I wanted him to stay clean. So I would invite him over and I'd tell him what the plans were for the character. I'd say, look, he's been in prison for a few years, so you've got to get that yoked prison body. Because I wanted him to start working out and taking care of himself. You know, season 1 he was supposed to die at the end and I couldn't do it. On May 31, 2026, the same day that the final episode of the third season was released, HBO confirmed that the series had concluded after three seasons. In an interview with The New York Times, Levinson elaborated on his decision to end the series and stated: "In terms of the story that we set out to tell, which is a story about addiction and its consequences, this feels like the end to me".
==== The tandem principle ==== The solution emerged from a charge-reversal concept proposed demonstrated by Nobel laureate Luis Alvarez in 1951. Rather than accelerate positive ions from ground to a high-voltage terminal, the tandem accelerator begins with negative ions. These particles accelerate toward a positive terminal, where a thin foil or gas stripper removes multiple electrons, converting them to positive ions. The now-positive particles accelerate away from the terminal back to ground potential. This double acceleration effectively multiplies the particle energy without requiring proportionally higher terminal voltages. A negative hydrogen ion accelerated through a 5 megavolt tandem emerges with 10 megavolts of kinetic energy. After commissioning tandem production in 1954, Atomic Energy of Canada Limited placed HVEC's first tandem order in September 1956 for $0.92M (equivalent to $10.89M in 2025). The machine achieved first beam at HVEC's Burlington facility in June 1958.
=== Sea freight === The Transnet National Ports Authority owns, and is for the most part responsible for operations of, South Africa's eight commercial seaports. Around 60% of all South African imports and exports pass through the Port of Durban, which consists of 58 berths ranging from 148m to 350m, with depths of up to 12.2m. Other significant seaports in terms of cargo volumes include the Port of Cape Town, the Port of Gqeberha, and the Port of Ngqura. Transnet National Ports Authority statistics for cargo processed each year in South Africa are below.
== Further reading == FDA 21 CFR 113.3 Thermally processed low acid foods packaged in hermetically sealed containers Revision Apr. 2006 Potter, N. N. and Hotchkiss, J. H. Food Science (5th ed). Springer, 1999 Fellows, P. J. Food Processing Technology: Principles and Practice (2nd Edition). Woodhead Pub. 1999 Zeide, Anna (6 March 2018). Canned: The Rise and Fall of Consumer Confidence in the American Food Industry. University of California Press. ISBN 978-0520290686.
Sources: en.wikipedia.org
==== Native Wagyu ==== Native Wagyu (在来和牛, zairai wagyū) are cattle from ancient Japan that have not been crossbred with foreign breeds. It is also called "Japanese breed," "pure Japanese breed," "pure Wagyu," etc. There are two breeds of native Wagyu as follows:
Native to cold temperate coastal areas of Japan, Korea, China, and Russia, in recent decades it has become established in temperate regions around the world, including New Zealand, the United States, Belgium, France, Great Britain, Spain, Italy, Argentina, Australia and Mexico. It was nominated one of the 100 worst invasive species in the world. Undaria is commonly initially introduced or recorded on artificial structures, where its r-selected growth strategy facilitates proliferation and spread to natural reef sites. Undaria populations make a significant but inconsistent contribution of food and habitat to intertidal and subtidal reefs. Undaria invasion can cause changes to native community composition at all trophic levels. As well as increasing primary productivity, it can reduce the abundance and diversity of understory algal assemblages, out-compete some native macroalgal species and affect the abundance and composition of associated epibionts and macrofauna, including gastropods, crabs, urchins and fish. Its dense congregation and capability to latch onto any hard surface has caused it to become a major cause of damage to aquaculture apparatus, decreasing efficiency of fishing industries by clogging underwater equipment and fouling boat hulls. Eradication of wakame within a localized area usually involves getting rid of the algae underwater, often via regular inspection of aquatic environments.
== Products == Novo produces the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
== Supplementation == Exogenous DAO (supplements) are being studied as complementary treatment for the relief of symptoms associated with histamine intolerance, and for the relief of other conditions, such as migraine or fibromyalgia. However, the results are inconclusive because studies to date have involved small study populations and short intervention periods. In the United States, DAO supplements are available over the counter but are not FDA-approved. In Europe, two investigations, financially backed by the manufacturer of the oral DAO supplementation, have posited that DAO supplementation could alleviate patient symptoms. The first study sought to "objectify and quantify histamine-associated symptoms and to analyze whether oral administration of the histamine-degrading enzyme DAO caused a reduction of symptoms". In this study, neither major nor minor symptoms could be replicated in 39 patients who initially responded to an open challenge with 75 mg histamine in peppermint tea, using a double-blind, placebo-controlled challenge. Consequently, the primary endpoint of the study was not achieved, and the basis for the authors' conclusion that DAO supplementation intake resulted in a "statistically significant reduction in symptoms" remains unclear. The second study was purely observational, lacking a control group: it compared symptomatology with and without DAO use in 28 patients. The chosen design was not suitable to demonstrate causal effects and carried a high risk of attributing placebo effects.
Sources: en.wikipedia.org
=== Ovulation === NGF is abundant in seminal plasma. Recent studies have found that it induces ovulation in some mammals e.g. "induced" ovulators, such as llamas. Surprisingly, research showed that these induced animals will also ovulate when semen from on-schedule or "spontaneous" ovulators, such as cattle is used. Its significance in humans is unknown. It was previously dubbed ovulation-inducing factor (OIF) in semen before it was identified as beta-NGF in 2012.
Papaverine is also present in combinations of opium alkaloid salts such as papaveretum (Omnopon, Pantopon) and others, along with morphine, codeine, and in some cases noscapine and others in a percentage similar to that in opium, or modified for a given application. Papaverine is found as a contaminant in some heroin and can be used by forensic laboratories in heroin profiling to identify its source. The metabolites can also be found in the urine of heroin users, allowing street heroin to be distinguished from pharmaceutical diacetylmorphine.
=== 1980 === January 3–4: President Jimmy Carter withdraws the SALT II Treaty from Senate confirmation and bans technology sales to the Soviet Union. January 27: The Carter Doctrine commits the United States to defending the Gulf States from external invasion. February 13: Britain's MI6 commences its indirect and direct covert operations in Afghanistan, to support the Afghan mujahideen against Soviet intervention. February 25: A military coup occurred in Suriname eventually lead to the establishment of a military regime in the country. March 21: The United States and its allies boycott the 1980 Summer Olympics (July 15 – August 3) in Moscow. April 17: Robert Mugabe becomes Prime Minister of Zimbabwe. April 30: Iranian Embassy in London is taken over by DRFLA militants starting a 6-day-long hostage situation. May 4: Josip Broz Tito, communist leader of Yugoslavia since 1945, dies at the age of 87 in Ljubljana. May 17: Peru begins experiences a civil conflict between the government and the Marxist–Leninist guerilla groups, most notably the Shining Path. May 18–27: An anti-government uprising occurred in Gwangju, South Korea. 3 July: the CIA begins Operation Cyclone - a program to arm and finance the Afghan mujahideen fighting the Soviets in Afghanistan. August 31: In Poland, the Gdańsk Agreement is signed after a wave of strikes which began at the Lenin Shipyards in Gdańsk. The agreement allows greater civil rights, such as the establishment of a trade union, known as Solidarity, independent of communist control.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.